Levodopa and decarboxylase inhibitors - search results

European Union - English - EMA (European Medicines Agency)

levodopa/carbidopa/entacapone orion

orion corporation - levodopa, carbidopa, entacapone - parkinson disease - nervous system - levodopa/carbidopa/entacapone orion is indicated for the treatment of adult patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (ddc)-inhibitor treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

apo-levodopa/carbidopa 250/25 levodopa 250 mg and carbidopa (as monohydrate) 25 mg tablet blister pack

arrotex pharmaceuticals pty ltd - levodopa, quantity: 250 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; crospovidone; pregelatinised maize starch; indigo carmine aluminium lake - apo-levodopa/carbidopa is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. apo-levodopa/carbidopa frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

European Union - English - EMA (European Medicines Agency)

corbilta (previously levodopa/carbidopa/entacapone sandoz)

orion corporation - levodopa, carbidopa, entacapone - parkinson disease - anti-parkinson drugs - corbilta is indicated for the treatment of adult patients with parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Ireland - English - HPRA (Health Products Regulatory Authority)

carbidopa/levodopa fair-med 12.5mg/50mg tablets

fairmed healthcare gmbh - levodopa; carbidopa - tablet - 12.5/50 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor

Australia - English - Department of Health (Therapeutic Goods Administration)

apo-levodopa/carbidopa 100/25 levodopa 100 mg and carbidopa (as monohydrate) 25 mg tablet blister pack

arrotex pharmaceuticals pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 100 mg - tablet, uncoated - excipient ingredients: crospovidone; quinoline yellow aluminium lake; microcrystalline cellulose; magnesium stearate; pregelatinised maize starch - apo-levodopa/carbidopa is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. apo-levodopa/carbidopa frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

Ireland - English - HPRA (Health Products Regulatory Authority)